Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity.

@article{Byrd2001RituximabUA,
  title={Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity.},
  author={John C. Byrd and Tanya Murphy and Robin Simon Howard and Margaret S Lucas and Amy L. Goodrich and Kyung Ja Park and Michael W Pearson and Jamie K. Waselenko and Galina Ling and Michael R Grever and Antonio J. Grillo-L{\'o}pez and Julie Rosenberg and L. O. Kunkel and Ian W Flinn},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2001},
  volume={19 8},
  pages={2153-64}
}
PURPOSE Rituximab has been reported to have little activity in small lymphocytic lymphoma (SLL)/chronic lymphocytic leukemia (CLL) and to be associated with significant infusion-related toxicity. This study sought to decrease the initial toxicity and optimize the pharmacokinetics with an alternative treatment schedule. PATIENTS AND METHODS Thirty three patients with SLL/CLL received dose 1 of rituximab (100 mg) over 4 hours. In cohort I (n = 3; 250 mg/m(2)) and cohort II (n = 7; 375 mg/m(2… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 185 extracted citations

Monoclonal antibodies in oncology therapeutics: present and future indications.

Expert opinion on biological therapy • 2013
View 8 Excerpts
Highly Influenced

Rituximab for the treatment of patients with chronic lymphocytic leukemia

Cancer management and research • 2010
View 3 Excerpts
Highly Influenced

Chronic lymphocytic leukemia: diagnosis and treatment.

Mayo Clinic proceedings • 2006
View 7 Excerpts
Highly Influenced

Monoclonal antibody therapy of chronic lymphocytic leukemia

Cancer Immunology, Immunotherapy • 2005
View 4 Excerpts
Highly Influenced

Similar Papers

Loading similar papers…